MARKET

SRNE

SRNE

Sorrento Thera
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.97
0.00
0.00%
After Hours: 7.88 -0.09 -1.13% 19:59 12/04 EST
OPEN
7.96
PREV CLOSE
7.97
HIGH
8.17
LOW
7.83
VOLUME
8.94M
TURNOVER
--
52 WEEK HIGH
19.39
52 WEEK LOW
1.550
MARKET CAP
2.10B
P/E (TTM)
-5.4792
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Thinking about buying stock in AMC Entertainment, Inovio Pharmaceuticals, Sundial Growers, Nikola Corp, or Sorrento Therapeutics?
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMC, INO, SNDL, NKLA, and SRNE.
PR Newswire - PRF · 4d ago
Sorrento to Participate in the 32nd Piper Sandler Healthcare Investor Conference
GlobeNewswire · 5d ago
SmarTrend Watching for Potential Pullback in Shares of Sorrento Therape After 18.55% Gain
Sorrento Therape (NASDAQ:SRNE) traded in a range yesterday that spanned from a low of $7.60 to a high of $8.30. Yesterday, the shares gained 18.6%, which took the trading range above the 3-day high of $7.62 on volume of 4.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Comtex SmarTrend(R) · 11/27 17:28
Mid-Day Market Update: Nasdaq Surges 100 Points; Sorrento Therapeutics Shares Spike Higher
Midway through trading Friday, the Dow traded up 0.04% to 29,883.70 while the NASDAQ rose 0.86% to 12,197.94. The S&P also rose, gaining 0.17% to 3,635.88.
Benzinga · 11/27 17:20
Sorrento Receives $34M Federal Contract for Covid Treatment
The money will pay for development through Phase 2 clinical studies of a gene-encoded antibody, Sorrento said.
TheStreet.com · 11/27 15:37
Sorrento Gets DARPA Contract For Up To $34M To Develop Neutralizing Antibodies For COVID-19
Sorrento Therapeutics Inc (NASDAQ: SRNE) shares, which have been given to much volatility, are rallying sharply Friday.
Benzinga · 11/27 15:25
Thinking about buying stock in Sorrento Therapeutics, Blink Charging, Dolphin Entertainment, FuelCell Energy, or Gevo Inc?
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SRNE, BLNK, DLPN, FCEL, and GEVO.
PR Newswire - PRF · 11/27 14:31
Sorrento Therapeutics rallies on DARPA-JPEO contract to SmartPharm
Defense Advanced Research Projects Agency ((DARPA)) co-funded by the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) awarded SmartPharm Therapeutics, wholly-owned subsidiary of Sorrento Therapeutics (SRNE) +17% PM,
Seekingalpha · 11/27 13:33
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SRNE. Analyze the recent business situations of Sorrento Thera through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SRNE stock price target is 25.50 with a high estimate of 30.00 and a low estimate of 21.00.
EPS
Institutional Holdings
Institutions: 267
Institutional Holdings: 77.13M
% Owned: 29.33%
Shares Outstanding: 262.94M
TypeInstitutionsShares
Increased
82
14.34M
New
91
714.61K
Decreased
39
4.34M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.89%
Pharmaceuticals & Medical Research
+1.72%
Key Executives
Chairman/President/Chief Executive Officer/Co-Founder/Director
Henry Ji
Chief Financial Officer
Najjam Asghar
Lead Director/Independent Director
Dorman Followwill
Director
Kim Janda
Director
Jaisim Shah
Independent Director
Edgar Lee
Independent Director
David Lemus
Independent Director
Robin Smith
Independent Director
Yue Wu
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About SRNE
Sorrento Therapeutics, Inc. is a clinical-stage and commercial biopharma company. The Company operates through two segments: Sorrento Therapeutics and Scilex. The Sorrento Therapeutics segment is organized around its Immune-Oncology therapeutic area, leveraging its G-MAB antibody library and targeted delivery modalities to generate the next generation of cancer therapeutics. These modalities include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy (DAR-T), antibody-drug conjugates (ADC), as well as bispecific antibody approaches. Additionally, Sorrento Therapeutics segment also includes Sofusa, a drug delivery technology that delivers biologics directly into the lymphatic system to potentially achieve improved efficacy and fewer adverse effects than standard parenteral immunotherapy. The Scilex segment is organized around its non-opioid pain management operations.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Sorrento Therapeutics Inc stock information, including NASDAQ:SRNE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SRNE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SRNE stock methods without spending real money on the virtual paper trading platform.